Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
NCT ID: NCT05125978
Last Updated: 2023-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2026-09-30
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Tiradentes Association in the Treatment of Acute Pain
NCT04593329
An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain
NCT01112267
A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen
NCT01819805
Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic Origin
NCT05324059
A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets
NCT00642837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Canadá association
The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:
1 tablet Canadá, oral;
1 placebo tablet of tramadol, oral;
1 placebo tablet of dipyrone, oral.
Canadá
Canadá association 1 tablet twice a day
Dipyrone placebo
Placebo of dipyrone 1 tablet twice a day
Tramadol hydrochloride placebo
Placebo of tramadol 1 coated tablet twice a day
Tramadol
The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:
1 tablet tramadol, oral;
1 placebo tablet of Canadá, oral;
1 placebo tablet of dipyrone, oral.
Canadá placebo
Placebo of Canadá association 1 tablet twice a day
Dipyrone placebo
Placebo of dipyrone 1 tablet twice a day
Tramadol hydrochloride
Tramadol 1 coated tablet twice a day
Dipyrone
The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:
1 tablet dipyrone, oral;
1 placebo tablet of tramadol, oral;
1 placebo tablet of Canadá, oral.
Canadá placebo
Placebo of Canadá association 1 tablet twice a day
Dipyrone
Dipyrone 1 tablet twice a day
Tramadol hydrochloride placebo
Placebo of tramadol 1 coated tablet twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Canadá
Canadá association 1 tablet twice a day
Canadá placebo
Placebo of Canadá association 1 tablet twice a day
Dipyrone
Dipyrone 1 tablet twice a day
Dipyrone placebo
Placebo of dipyrone 1 tablet twice a day
Tramadol hydrochloride
Tramadol 1 coated tablet twice a day
Tramadol hydrochloride placebo
Placebo of tramadol 1 coated tablet twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic pain during at least 3 months.
Exclusion Criteria
* History of alcohol abuse or illicit drug use;
* Participation in a clinical trial in the year prior to this study;
* Pregnancy or risk of pregnacy and lactating participants;
* Known hypersensitivity to any of the formula compounds.
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EMS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMS1120 - CANADÁ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.